Description of Medical ServiceTisagenlecleucel is an autologous, murine anti-CD19 chimeric antigen receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical ConditionAcute lymphoblastic leukaemia (ALL) is the malignant proliferation of lymphoid progenitor cells in the bone marrow.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin lymphoma (NHL).
Reason for ApplicationNew non-MBS item
Medical Service TypeHybrid health technology
Previous Application NumberNot Applicable
Application FormApplication Form (PDF 842 KB)
Application Form (Word 498 KB)
PICO ConfirmationPICO Confirmation (PDF 1458 KB)
PICO Confirmation (Word 743 KB)
Public Summary DocumentPublic Summary Document (PDF 1116 KB)
Public Summary Document (Word 126 KB)
Meetings for this Application
PASC12-13 April 2018
ESC5 October 2018
MSAC22-23 November 2018
28-29 March 2019
9 April 2019